-+ 0.00%
-+ 0.00%
-+ 0.00%

Phase 1B CHM CORE-NK trial advances to newly diagnosed AML

ASX·12/15/2024 22:50:00

The content of this announcement was automatically generated by machine and is for reference only. The original announcement can be viewed by clicking on the link below.